BPC-157s ability to heal ocular tissues and its established relationship with the NO-system suggest it could mitigate the symptoms of dry eye, which range from discomfort to severe visual impairment
In particular, the immediate recovery of collaterals and bypassing of the obstruction, a feature noted in the present study, and the rapid reestablishment of blood flow in both the ischemic and reperfusion conditions may be responsible for its subsequent strong angiogenic effect and its healing effects[2,22-28], which are more pronounced than those of standard anti-ulcer agents[23]
Results tend to be strongest in individuals with deficiency or increased demand
Unlicensed synthetic nootropics may be considered controlled substances under the Psychoactive Substances Act
Pharmacokinetic analysis revealed it to be orally active with significantly increased metabolic stability, exhibiting a plasma half-life of 335.5 minutes, allowing for prolonged systemic availability [2]
